Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma.

Journal of cancer research and therapeutics - 1 Jan 2000

Peters Marieke A, Geukes Foppen Marnix H, Blank Christian U, Crijns Marianne B

Abstract excerpt

With the discovery of v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors, new treatment possibilities arose against metastatic melanoma. A frequent adverse effect of BRAF inhibitor therapy is the induction of epithelial proliferations such as cutaneous squamous cell carcinoma and verrucous papilloma. Here, we describe a case in which a patient developed extensive anal epithelial proliferations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anus Neoplasms
Share to Condylomata Acuminata

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Neoplasms, Glandular and Epithelial

Share to Papillomaviridae

Share to Papillomavirus Infections

Share to Skin Neoplasms

Share to Vemurafenib

Source

Identifiers

PMID: 32362631
DOI: 10.4103/jcrt.JCRT_317_17

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma.PMID 32362631Read ↗

Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.Semantic proximity Read ↗

Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.Semantic proximity Read ↗

Dermatological adverse events from BRAF inhibitors: a growing problem.Semantic proximity Read ↗

Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next?Semantic proximity Read ↗

Impact of BRAF and MEK Inhibitors on Gingival Hyperplasia in Melanoma PatientsSemantic proximity Read ↗

No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients.Semantic proximity Read ↗

Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.Semantic proximity Read ↗

Human papillomaviruses and non-melanoma skin cancerSemantic proximity Read ↗

Nonmalignant cutaneous findings associated with vemurafenib.Semantic proximity Read ↗

High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.Semantic proximity Read ↗

Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.Semantic proximity Read ↗

BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.